Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced the resignation of Mr. Ajay Rawat, Assistant Vice President – Research and Development, who is designated as Senior Management Personnel. His resignation was accepted by the management on August 19, 2026, and will be effective from the close of business hours on November 13, 2026. Mr. Rawat cited pursuing career opportunities outside the company as the reason for his departure. The company has provided the necessary disclosures as per SEBI regulations.

Tatva Chintan Pharma Chem Ltd announced that its Board of Directors recommended a final dividend of ₹2.00 per equity share (20%) for the financial year ended March 31, 2026. This dividend is subject to shareholder approval at the upcoming 30th Annual General Meeting. The company also provided details regarding Tax Deduction at Source (TDS) for both resident and non-resident shareholders, outlining applicable rates and conditions for tax exemption or lower withholding tax, including the requirement for specific forms and declarations.

Tatva Chintan Pharma Chem Ltd announced the Groundbreaking Ceremony (Bhoomi Pujan) for its new greenfield manufacturing unit at Dahej - III, Gujarat. This event, held on July 20, 2026, follows an earlier intimation on July 17, 2026. The new facility is a strategic move to bolster the company's infrastructure and cater to increasing market demands, aligning with its growth strategy. The company will make this information available on its website.

Tatva Chintan Pharma Chem Limited's Board of Directors approved a significant capacity expansion for specialty chemicals at their new greenfield unit in Dahej, Gujarat. This expansion aims to strengthen infrastructure and meet growing market demands. Additionally, the board approved an increase in the company's borrowing limits from ₹300 crore to ₹1,000 crore, subject to shareholder approval. The meeting also saw the approval of unaudited financial results for the quarter ended June 30, 2026, and the re-appointment of three key directors: Mr. Chintan Nitinkumar Shah (Managing Director), Mr. Ajaykumar Mansukhlal Patel (Whole-time Director), and Mr. Shekhar Rasiklal Somani (Whole-time Director), each for a three-year term starting February 1, 2027.

Tatva Chintan Pharma Chem Limited's Board of Directors, in a meeting held on July 17, 2026, approved the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026, along with the limited review report. The board also approved the re-appointment of Mr. Chintan Nitinkumar Shah as Managing Director and Mr. Ajaykumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani as Whole-time Directors, each for a further period of three years from February 1, 2027, subject to shareholder approval. Additionally, the company greenlit a capacity expansion for specialty chemicals at its Dahej unit and an increase in borrowing limits from ₹300 crore to ₹1,000 crore, also pending member approval.

Tatva Chintan Pharma Chem Limited's Board of Directors met on July 17, 2026, approving the unaudited financial results for Q1 FY27 (standalone and consolidated). Key decisions included the re-appointment of three directors: Mr. Chintan Nitinkumar Shah (Managing Director), Mr. Ajaykumar Mansukhlal Patel (Whole-time Director), and Mr. Shekhar Rasiklal Somani (Whole-time Director), each for a three-year term starting February 1, 2027. The board also greenlit a significant capacity expansion for specialty chemicals at their new Dahej greenfield unit and approved an increase in the company's borrowing limits from ₹300 crore to ₹1,000 crore, subject to shareholder approval.

Tatva Chintan Pharma Chem opened FY27 with a decisively strong quarter. Consolidated revenue from operations rose 42.9% YoY to ₹167.1 Cr (up 24.5% sequentially) and consolidated PAT jumped 140% YoY to ₹15.98 Cr, with basic EPS at ₹6.83 versus ₹2.84 a year ago. Net margin expanded to 9.6% from 5.6% a year earlier and 7.7% last quarter — the profit growth ran well ahead of revenue, driven by operating leverage on a higher topline. Notably, the reported profit absorbs a ₹1.32 Cr exceptional loss (unexplained in the notes) that was absent last year; excluding it, underlying PAT is ~₹17.3 Cr, or roughly +160% YoY — so the headline understates the operating improvement rather than flattering it. Against management's own FY27 guidance of ~25% revenue growth with 20-22% EBITDA margins, the print beats comfortably on growth (Q1 revenue +43% YoY) but sits marginally below the margin band — estimated operating margin was ~19.3%, a touch under the 20-22% target and softer than last quarter's 21%, worth watching as the raw-material pass-through story management flagged plays out. The bullish, confident tone from the Q4 concall is confirmed by these numbers. On street expectations, no specific quarterly consensus estimate surfaced; available analyst coverage (Univest, May-26) carries a 12-month price target of ~₹1,200 with Q1 flagged as the key confirmation checkpoint — a bar this print clears on growth. Consolidated substantially outpaces standalone: standalone PAT was ₹10.45 Cr (+103% YoY) on ₹146.7 Cr revenue, meaning the wholly-owned US and Europe subsidiaries contributed a material share of the group's growth — readers comparing the two numbers should note the ~37-point growth gap reflects subsidiary strength, not an error in either figure. The same board meeting paired the result with two growth-capital actions: approval of a new greenfield capacity addition at Dahej-III (aggregate reactor capacity of 344 KL, ~₹200 Cr capex over ~21 months, funded via internal accruals and debt) and a hike in the borrowing limit from ₹300 Cr to ₹1,000 Cr. Together with the MD/whole-time director re-appointments, this signals the company is gearing its balance sheet for the next capacity-led leg management has been guiding toward.

Tatva Chintan Pharma Chem Ltd has announced a Board of Directors meeting scheduled for July 17, 2026. The primary agenda is to consider, approve, and take on record the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. In line with the company's insider trading code, the trading window for designated persons will be closed from July 1, 2026, until 48 hours after the financial results are publicly disclosed. The information is also available on the company's website.

Tatva Chintan Pharma Chem Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code. The trading window will be shut from Wednesday, July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. During this period, no trading in the company's securities is permitted for these individuals.

Tatva Chintan Pharma Chem Ltd's board re-appointed M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for the financial year 2026-27. These appointments, based on the Audit Committee's recommendation, were approved during the board meeting held on May 16, 2026. The board also approved the audited financial results for the quarter and year ended March 31, 2026, and recommended a final dividend of ₹2 per equity share, subject to shareholder approval.